Skip to main content

Table 2 Risk of arterial thromboembolism at 30 days and 365 days following ICU admission in patients with and without atrial fibrillation and by pre-admission use of aspirin and vitamin K antagonists

From: Pre-existing atrial fibrillation and risk of arterial thromboembolism and death in intensive care unit patients: a population-based cohort study

 

30-day ATE risk

365-day ATE risk

 

AF

No AF

AF

No AF

Overall

    

Cumulative risk, %

2.8 (2.4–3.3)

2.0 (1.9–2.2)

4.3 (3.7–4.9)

2.9 (2.7–3.0)

Cumulative risk ratio

    

  Crude

1.41 (1.19–1.67)

1 (ref)

1.50 (1.31–1.73)

1 (ref)

  Adjusteda

1.14 (0.93–1.40)

1 (ref)

1.20 (1.02–1.41)

1 (ref)

Aspirin users

    

Cumulative risk, %

    

  Non-users

2.5 (2.0–3.1)

2.0 (1.8–2.1)

3.7 (3.1–4.4)

2.7 (2.5–2.8)

  Users

3.4 (2.6–4.2)

2.4 (2.1–2.7)

5.1 (4.1–6.1)

3.5 (3.2–3.9)

Cumulative risk ratio

    

  Non-users

1 (ref)

1 (ref)

1 (ref)

1 (ref)

  Users, crude

1.35 (0.98–1.86)

1.21 (1.05–1.40)

1.36 (1.05–1.77)

1.31 (1.17–1.47)

  Users, adjusteda

1.05 (0.64–1.75)

0.78 (0.65–0.93)

1.13 (0.81–1.59)

0.81 (0.70–0.95)

Vitamin K antagonist users

    

Cumulative risk, %

    

  Non-users

3.4 (2.7–4.1)

2.0 (1.9–2.2)

4.9 (4.1–5.7)

2.9 (2.7–3.0)

  Users

2.4 (1.8–3.0)

1.9 (1.2–2.7)

3.7 (2.9–4.4)

3.1 (2.2–4.0)

Cumulative risk ratio

    

  Non-users

1 (ref)

1 (ref)

1 (ref)

1 (ref)

  Users, crude

0.70 (0.50–0.96)

0.95 (0.65–1.39)

0.75 (0.58–0.97)

1.07 (0.79–1.46)

  Users, adjusteda

0.57 (0.26–1.25)

0.71 (0.46 -1.12)

0.76 (0.50–1.16)

0.82 (0.58–1.16)

  1. AF atrial fibrillation, ATE arterial thromboembolism
  2. 95 % confidence intervals are given in parentheses
  3. aAdjusted for the risk factors included in the CHA2DS2-VASc score (i.e., congestive heart failure, hypertension, age, diabetes, prior stroke, vascular diseases, and sex category)
Back to article page

Critical Care

ISSN: 1364-8535